TAK-079
E852350
TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| TAK-079 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10292093 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: TAK-079 Context triple: [CD38, targetOf, TAK-079]
-
A.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
B.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
E.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: TAK-079 Target entity description: TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
-
A.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
B.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
E.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
- F. None of above. chosen
Statements (29)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medicinal product
ⓘ
investigational drug ⓘ monoclonal antibody ⓘ |
| actsOn |
CD38-positive immune cells
ⓘ
CD38-positive malignant plasma cells ⓘ |
| bindsTo | CD38-expressing cells ⓘ |
| developedBy | Takeda Pharmaceutical Company Limited NERFINISHED ⓘ |
| developedForIndication |
autoantibody-mediated diseases
ⓘ
autoimmune diseases ⓘ multiple myeloma ⓘ systemic lupus erythematosus ⓘ |
| hasDevelopmentStatus | investigational ⓘ |
| hasIntendedEffect | depletion of CD38-expressing cells ⓘ |
| hasMechanismOfAction |
antibody-dependent cellular cytotoxicity
ⓘ
apoptosis induction in CD38-positive cells ⓘ complement-dependent cytotoxicity ⓘ |
| hasMoleculeType | human monoclonal antibody ⓘ |
| hasRouteOfAdministration | subcutaneous administration ⓘ |
| hasSpeciesOrigin | human ⓘ |
| hasTarget | CD38 NERFINISHED ⓘ |
| hasTherapeuticArea |
hematology
ⓘ
immunology ⓘ oncology ⓘ |
| isAdministeredAs | parenteral formulation ⓘ |
| isComparedWith | other anti-CD38 antibodies ⓘ |
| isDesignedTo |
modulate immune system activity
ⓘ
reduce pathogenic autoantibodies ⓘ |
| targetsCellType |
CD38-positive lymphocytes
ⓘ
plasma cells ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: TAK-079 Description of subject: TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.